PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32226300-8	2020	Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib.	bmdc	23-27	epidermal growth factor receptor	Homo sapiens	82-86
30984180-5	2019	We investigated the effects of vitamin D on murine CD11c+ bone marrow derived DC (BMDC) function by analyzing global gene expression in CD11c+ BMDC generated in the presence (VitD-CD11c+BMDC) or absence (Veh-CD11c+BMDC) of the active vitamin D metabolite, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3).	bmdc	82-86	integrin alpha X	Mus musculus	51-56
32106265-10	2020	Blockade of ACC1 resulted in metabolic reprogramming of BMDC that ameliorated mitochondrial dysfunction and reduced pathologic innate immune cytokines in DC.	bmdc	56-60	acetyl-CoA carboxylase alpha	Homo sapiens	12-16
30561085-10	2019	CONCLUSION: Exosomes derived from LIPUS-treated BMDC inhibit TNFalpha-induced endothelial inflammation by inhibiting the nuclear factor-kappaB signaling pathway.	bmdc	48-52	tumor necrosis factor	Homo sapiens	61-69
29912595-9	2019	The co-incubation of BMDC with supernatants of activated, irradiated pMF significantly reduced the CD40 expression, but did not impact on the BMDC-derived induction of T-cell proliferation.	bmdc	21-25	CD40 antigen	Mus musculus	99-103
27857212-3	2016	We investigated the effects of CpdA on in vitro generated GM-CSF-conditioned bone marrow-derived DC (BMDC).	bmdc	101-105	colony stimulating factor 2	Homo sapiens	58-64
29390039-6	2018	Finally, BMDC lacking SAA3 demonstrate an impaired endotoxin tolerance response and inhibited responses to retinoic acid.	bmdc	9-13	serum amyloid A 3	Mus musculus	22-26
29218051-5	2017	From 24 h on after CLP, BMC gave rise to BMDC that released enhanced levels of IL-10.	bmdc	41-45	interleukin 10	Mus musculus	79-84
29218051-7	2017	Prior depletion of the CD11chiMHCII+CD4+ DCs from BMC in vitro reversed the increased IL-10 secretion of subsequently differentiating BMDC.	bmdc	134-138	CD4 antigen	Mus musculus	36-39
29218051-7	2017	Prior depletion of the CD11chiMHCII+CD4+ DCs from BMC in vitro reversed the increased IL-10 secretion of subsequently differentiating BMDC.	bmdc	134-138	interleukin 10	Mus musculus	86-91
28202390-7	2017	RPE65-BMDC administration was most effective in early disease, when visual function and retinal morphology returned to near normal, and less effective in late-stage disease.	bmdc	6-10	retinal pigment epithelium 65	Mus musculus	0-5
27815442-5	2016	We show that murine bone marrow-derived DC (BMDC) maturation induced by LPS, as opposed to polyinosinic:polycytidylic acid or cytosine-phosphate-guanine, is robustly inhibited by vascular endothelial growth factor (VEGF), a previously identified immunosuppressive cytokine.	bmdc	44-48	vascular endothelial growth factor A	Mus musculus	179-213
27815442-5	2016	We show that murine bone marrow-derived DC (BMDC) maturation induced by LPS, as opposed to polyinosinic:polycytidylic acid or cytosine-phosphate-guanine, is robustly inhibited by vascular endothelial growth factor (VEGF), a previously identified immunosuppressive cytokine.	bmdc	44-48	vascular endothelial growth factor A	Mus musculus	215-219
27815442-8	2016	However, NRP-1-deficient BMDC remained completely insensitive to the VEGF-dependent inhibition of BMDC maturation in culture.	bmdc	25-29	neuropilin 1	Mus musculus	9-14
27466155-4	2016	In this study we showed that rapamycin treatment on RSV-infected murine bone marrow-derived DC (BMDC) decreases the frequency of CD8(+)CD44(high) T cells.	bmdc	96-100	CD8a molecule	Homo sapiens	129-132
27466155-5	2016	However, inhibition of mTOR on RSV-infected BMDC did not modify the activation phenotype of these cells.	bmdc	44-48	mechanistic target of rapamycin kinase	Homo sapiens	23-27
26635791-7	2015	Instead, we discovered that the addition of 1,25(OH)2D3 to BMDC cultures resulted in a significant reduction in the proportion of CD11c+ cells.	bmdc	59-63	integrin subunit alpha X	Homo sapiens	130-135
26519533-7	2015	injection of IgM/LPS-pretreated BMDC or using IL-10 knockout BMDC fails to induce protection.	bmdc	61-65	interleukin 10	Mus musculus	46-51
26519533-8	2015	Similarly, IgM/LPS-pretreated BMDC are rendered nonprotective by increasing CD40 expression and phosphorylation of p65 NF-kappaB.	bmdc	30-34	CD40 antigen	Mus musculus	76-80
26519533-8	2015	Similarly, IgM/LPS-pretreated BMDC are rendered nonprotective by increasing CD40 expression and phosphorylation of p65 NF-kappaB.	bmdc	30-34	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	115-118
26635791-8	2015	Purified CD11c+ VitD-BMDC were significantly less effective at priming T cells in vitro yet were similarly capable of initiating EAE as vehicle-treated CD11c+ BMDC.	bmdc	21-25	integrin subunit alpha X	Homo sapiens	152-157
26549577-3	2015	BMDC treated with MG:OVA induced significantly higher numbers of activated (CD25+CD69+) OVA-specific CD4+ T cells than BMDC treated with OVA alone.	bmdc	0-4	interleukin 2 receptor subunit alpha	Homo sapiens	76-80
26549577-4	2015	BMDC treated with MG:OVA upregulated CD86 and CD40 expression as well as MG alone, indicating that conjugation of OVA does not alter the immunostimulatory capacity of MG. Activation of CD8+ OVA-specific OT-1 cells showed that MG:OVA is also capable of enhancing cross-presentation by BMDC to CD8+ cytotoxic T cells.	bmdc	0-4	CD40 molecule	Homo sapiens	46-50
26549577-4	2015	BMDC treated with MG:OVA upregulated CD86 and CD40 expression as well as MG alone, indicating that conjugation of OVA does not alter the immunostimulatory capacity of MG. Activation of CD8+ OVA-specific OT-1 cells showed that MG:OVA is also capable of enhancing cross-presentation by BMDC to CD8+ cytotoxic T cells.	bmdc	0-4	CD8a molecule	Homo sapiens	185-188
26549577-3	2015	BMDC treated with MG:OVA induced significantly higher numbers of activated (CD25+CD69+) OVA-specific CD4+ T cells than BMDC treated with OVA alone.	bmdc	0-4	CD69 molecule	Homo sapiens	81-85
26549577-3	2015	BMDC treated with MG:OVA induced significantly higher numbers of activated (CD25+CD69+) OVA-specific CD4+ T cells than BMDC treated with OVA alone.	bmdc	0-4	CD4 molecule	Homo sapiens	101-104
26083387-4	2015	Kdm5b-specific siRNA inhibition in BMDC led to a 10-fold increase in IFN-beta as well as increases in IL-6 and TNF-alpha compared to control-transfected cells.	bmdc	35-39	interleukin 6	Homo sapiens	102-106
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	bmdc	28-32	CD4 antigen	Mus musculus	69-72
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	bmdc	28-32	CD4 antigen	Mus musculus	110-113
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	bmdc	28-32	interleukin 2 receptor, alpha chain	Mus musculus	116-120
26083387-4	2015	Kdm5b-specific siRNA inhibition in BMDC led to a 10-fold increase in IFN-beta as well as increases in IL-6 and TNF-alpha compared to control-transfected cells.	bmdc	35-39	lysine demethylase 5B	Homo sapiens	0-5
26083387-4	2015	Kdm5b-specific siRNA inhibition in BMDC led to a 10-fold increase in IFN-beta as well as increases in IL-6 and TNF-alpha compared to control-transfected cells.	bmdc	35-39	tumor necrosis factor	Homo sapiens	111-120
25454807-0	2015	Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.	bmdc	82-86	interleukin 10	Mus musculus	25-30
26083387-4	2015	Kdm5b-specific siRNA inhibition in BMDC led to a 10-fold increase in IFN-beta as well as increases in IL-6 and TNF-alpha compared to control-transfected cells.	bmdc	35-39	interferon beta 1	Homo sapiens	69-77
25949867-7	2015	STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-beta signaling.	bmdc	146-150	signal transducer and activator of transcription 5A	Mus musculus	0-5
25949867-7	2015	STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-beta signaling.	bmdc	146-150	poly(rC) binding protein 1	Mus musculus	40-47
25949867-7	2015	STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-beta signaling.	bmdc	146-150	disabled 2, mitogen-responsive phosphoprotein	Mus musculus	108-112
25949867-7	2015	STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-beta signaling.	bmdc	146-150	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	131-137
25457882-5	2015	In contrast, the expression level of IFN-gamma and T-bet mRNA, signaling molecules for Th1 cells, was higher in peptide 19-immunized group than in PBS-immunized group.In non-immunized wild mice, BMDC-derived CD11c+ dendritic cells have shown to stimulate Tregs significantly in antigen-nonspecific manner.	bmdc	195-199	interferon gamma	Mus musculus	37-46
25457882-5	2015	In contrast, the expression level of IFN-gamma and T-bet mRNA, signaling molecules for Th1 cells, was higher in peptide 19-immunized group than in PBS-immunized group.In non-immunized wild mice, BMDC-derived CD11c+ dendritic cells have shown to stimulate Tregs significantly in antigen-nonspecific manner.	bmdc	195-199	T-box 21	Mus musculus	51-56
24347266-8	2014	However, when BMDCs from paclitaxel-treated mice were injected into wild-type EMT/6-bearing mice, a substantial increase in tumor growth and BMDC infiltration was detected compared to osteopontin-depleted EMT/6-bearing mice injected with BMDCs from paclitaxel-treated mice.	bmdc	14-18	IL2 inducible T cell kinase	Mus musculus	78-81
24347266-8	2014	However, when BMDCs from paclitaxel-treated mice were injected into wild-type EMT/6-bearing mice, a substantial increase in tumor growth and BMDC infiltration was detected compared to osteopontin-depleted EMT/6-bearing mice injected with BMDCs from paclitaxel-treated mice.	bmdc	14-18	secreted phosphoprotein 1	Mus musculus	184-195
24752333-6	2014	Collectively, our results suggest that the neutralization of VEGF-A in cultured tumor cells can block TMP-induced BMDC mobilization and colonization of tumors and hence provide another mechanism of action by which antiangiogenic drugs act to inhibit tumor growth and angiogenesis.	bmdc	114-118	vascular endothelial growth factor A	Mus musculus	61-67
24379281-2	2014	Spherules are the tissue form of Coccidioides, and we determined that the MR on bone marrow-derived dendritic cells (BMDC) was important for recognition of spherules (formalin-killed spherules [FKS]) and for secretion of interleukin 10 (IL-10) and proinflammatory cytokines in response to FKS by both elicited macrophages and BMDC.	bmdc	117-121	interleukin 10	Mus musculus	237-242
24078693-4	2013	Notably, Dox-induced production of mature IL-1beta was temporally correlated with caspase-8 activation in WT cells and greatly suppressed in Casp8(-/-)Rip3(-/-) or Trif(-/-) BMDC, as well as in WT BMDC treated with the caspase-8 inhibitor, IETD.	bmdc	174-178	interleukin 1 beta	Mus musculus	42-50
24295831-5	2014	Activation of PPARgamma enhanced the ability of BMDC to polarize CD4 T cells toward iTregs and to induce T cell expression of the mucosal homing receptor, CCR9.	bmdc	48-52	peroxisome proliferator activated receptor gamma	Mus musculus	14-23
24295831-5	2014	Activation of PPARgamma enhanced the ability of BMDC to polarize CD4 T cells toward iTregs and to induce T cell expression of the mucosal homing receptor, CCR9.	bmdc	48-52	chemokine (C-C motif) receptor 9	Mus musculus	155-159
24008730-6	2013	In comparison with untreated serum-starved BMDC, treatment with SAA downregulated mRNA expression of the pro-apoptotic molecule Bim, increased production of the pro-survival heat shock protein 70 (HSP70), and induced secretion of pro-inflammatory cytokines.	bmdc	43-47	serum amyloid A1 cluster	Homo sapiens	64-67
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	serum amyloid A1 cluster	Homo sapiens	0-3
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	CD4 molecule	Homo sapiens	106-109
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	interleukin 17A	Homo sapiens	132-138
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	interleukin 17F	Homo sapiens	140-146
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	interleukin 21	Homo sapiens	148-153
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	interleukin 22	Homo sapiens	155-160
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	interferon gamma	Homo sapiens	166-174
24008730-9	2013	Measurement of Dex-responsive gene expression demonstrated CD4(+) T cells as the target of glucocorticoid hyperresponsiveness manifest as a consequence of BMDC stimulation by SAA.	bmdc	155-159	CD4 molecule	Homo sapiens	59-62
24008730-9	2013	Measurement of Dex-responsive gene expression demonstrated CD4(+) T cells as the target of glucocorticoid hyperresponsiveness manifest as a consequence of BMDC stimulation by SAA.	bmdc	155-159	serum amyloid A1 cluster	Homo sapiens	175-178
23609581-4	2013	The results revealed that cembrane-type diterpenoids, especially lobocrassin B, effectively inhibited LPS-induced BMDC activation by inhibiting the production of TNF-alpha.	bmdc	114-118	tumor necrosis factor	Mus musculus	162-171
23269491-8	2013	In conclusion, this study indicates that Mt- and mouse HSP70-treated BMDC can suppress PGIA via an IL-10-producing T cell-dependent manner.	bmdc	69-73	heat shock protein 1B	Mus musculus	55-60
23269491-8	2013	In conclusion, this study indicates that Mt- and mouse HSP70-treated BMDC can suppress PGIA via an IL-10-producing T cell-dependent manner.	bmdc	69-73	interleukin 10	Mus musculus	99-104
22139376-10	2012	BMDC maturation was blunted by addition of an IFNbeta-neutralizing antibody.	bmdc	0-4	interferon beta 1, fibroblast	Mus musculus	46-53
22842304-5	2012	We also demonstrated that BMDC stimulation with Smteg resulted in significant IL-10 production.	bmdc	26-30	interleukin 10	Mus musculus	78-83
23478188-2	2013	Activation of adenosine A2A receptor (A2AR) is generally considered to be antiinflammatory, inhibiting BMDC activities to protect against ALI.	bmdc	103-107	adenosine A2a receptor	Mus musculus	14-36
23478188-2	2013	Activation of adenosine A2A receptor (A2AR) is generally considered to be antiinflammatory, inhibiting BMDC activities to protect against ALI.	bmdc	103-107	adenosine A2a receptor	Mus musculus	38-42
23853721-4	2013	Using chemical inhibitors specific to protein kinases involved in activation of Fc gamma receptors (FcgammaRs), which mediate IgG signals, we found that hyperphosphorylation of ERK1/2 and Syk phosphorylation occurred after stimulation of BMDC with LPS and IVIG, and the increasing effect on IL-10 production was abolished by these inhibitors.	bmdc	238-242	mitogen-activated protein kinase 3	Mus musculus	177-183
23853721-4	2013	Using chemical inhibitors specific to protein kinases involved in activation of Fc gamma receptors (FcgammaRs), which mediate IgG signals, we found that hyperphosphorylation of ERK1/2 and Syk phosphorylation occurred after stimulation of BMDC with LPS and IVIG, and the increasing effect on IL-10 production was abolished by these inhibitors.	bmdc	238-242	spleen tyrosine kinase	Mus musculus	188-191
23853721-6	2013	These findings suggest that IVIG induced the upregulation of IL-10 production through FcgammaRI activation, and IL-10 was indispensable to the suppressing effect of IVIG on the production of IL-12p70 in LPS-stimulated BMDC.	bmdc	218-222	interleukin 10	Mus musculus	112-117
23079132-3	2012	G1-4A, enhanced surface expression of CD40, CD80, CD86, MHCII by BMDC in vitro and splenic DC in vivo.	bmdc	65-69	CD40 antigen	Mus musculus	38-42
22517116-8	2012	Blocking TNFalpha receptor 1 (TNFR1) completely abolished chemokine production, suggesting that BMDC-derived TNFalpha induced airway epithelial cell activation and enhancement of the innate immune response.	bmdc	96-100	tumor necrosis factor	Mus musculus	9-17
21825928-2	2011	Intravenous granulocyte-colony stimulating factor (G-CSF) is known to induce mobilization of BMDC to peripheral blood and the tissue levels of the stromal cell derived factor-1 (SDF-1) to be key in their homing to sites of injury.	bmdc	93-97	colony stimulating factor 3	Rattus norvegicus	12-49
22517116-8	2012	Blocking TNFalpha receptor 1 (TNFR1) completely abolished chemokine production, suggesting that BMDC-derived TNFalpha induced airway epithelial cell activation and enhancement of the innate immune response.	bmdc	96-100	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	30-35
22517116-8	2012	Blocking TNFalpha receptor 1 (TNFR1) completely abolished chemokine production, suggesting that BMDC-derived TNFalpha induced airway epithelial cell activation and enhancement of the innate immune response.	bmdc	96-100	tumor necrosis factor	Mus musculus	109-117
22348129-6	2012	However, stimulated SHARPIN-deficient BMDC had reduced transcription and secretion of pro-inflammatory mediators IL6, IL12P70, GMCSF, and nitric oxide.	bmdc	38-42	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	127-132
22348129-8	2012	A mixed lymphocyte reaction showed that mutant BMDC only induced a weak Th1 immune response but stimulated increased Th2 cytokine production from allogeneic naive CD4(+) T cells.	bmdc	47-51	heart and neural crest derivatives expressed 2	Mus musculus	117-120
22348129-8	2012	A mixed lymphocyte reaction showed that mutant BMDC only induced a weak Th1 immune response but stimulated increased Th2 cytokine production from allogeneic naive CD4(+) T cells.	bmdc	47-51	CD4 antigen	Mus musculus	163-166
21978934-9	2011	Moreover, chimeric mice reconstituted with BMDC where MMP9 activity was attenuated did not support accelerated metastasis by carcinoma cells that were pretreated with chemotherapy before their introduction to host animals.	bmdc	43-47	matrix metallopeptidase 9	Mus musculus	54-58
21529994-3	2011	We show for the first time that the 24-hydroxylase enzyme is activated in bone marrow-derived dendritic cell (BMDC), due to 1,25(OH)2D3 stimulation which resulted in the induction of its gene, CYP24A1.	bmdc	110-114	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	193-200
21825928-2	2011	Intravenous granulocyte-colony stimulating factor (G-CSF) is known to induce mobilization of BMDC to peripheral blood and the tissue levels of the stromal cell derived factor-1 (SDF-1) to be key in their homing to sites of injury.	bmdc	93-97	colony stimulating factor 3	Rattus norvegicus	51-56
20933096-9	2011	The expression of stem cell markers (Sca-1 or c-kit) was detected in BMDC-treated SGs.	bmdc	69-73	ataxin 1	Mus musculus	37-42
21160046-5	2011	Adoptive transfer experiments of BMDC into naive mice revealed that BMDC from post-septic mice impaired Th1 priming but not Th cell expansion and suppressed the innate immune defense mechanisms against Pseudomonas bacteria in the lung.	bmdc	33-37	negative elongation factor complex member C/D, Th1l	Mus musculus	104-107
21160046-5	2011	Adoptive transfer experiments of BMDC into naive mice revealed that BMDC from post-septic mice impaired Th1 priming but not Th cell expansion and suppressed the innate immune defense mechanisms against Pseudomonas bacteria in the lung.	bmdc	68-72	negative elongation factor complex member C/D, Th1l	Mus musculus	104-107
21160046-6	2011	Accordingly, BMDC from post-septic mice inhibited the release of IFN-gamma from NK cells that are critical for the protection against Pseudomonas.	bmdc	13-17	interferon gamma	Mus musculus	65-74
20883723-7	2011	Finally, in vivo injection of GITR(-/-) OVA-loaded BMDC led to a lower cell number and a lower activated cell number in draining lymph nodes than in GITR(+/+) OVA-loaded BMDC injected mice.	bmdc	51-55	tumor necrosis factor receptor superfamily, member 18	Mus musculus	30-34
20883723-7	2011	Finally, in vivo injection of GITR(-/-) OVA-loaded BMDC led to a lower cell number and a lower activated cell number in draining lymph nodes than in GITR(+/+) OVA-loaded BMDC injected mice.	bmdc	51-55	tumor necrosis factor receptor superfamily, member 18	Mus musculus	149-153
20883723-7	2011	Finally, in vivo injection of GITR(-/-) OVA-loaded BMDC led to a lower cell number and a lower activated cell number in draining lymph nodes than in GITR(+/+) OVA-loaded BMDC injected mice.	bmdc	170-174	tumor necrosis factor receptor superfamily, member 18	Mus musculus	30-34
20933096-9	2011	The expression of stem cell markers (Sca-1 or c-kit) was detected in BMDC-treated SGs.	bmdc	69-73	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	46-51
20659463-9	2010	At 48 h post-infection, BMDC stimulated with LPS+IFN-gamma were able to eliminate the parasites.	bmdc	24-28	interferon gamma	Mus musculus	49-58
21057001-7	2010	Local iNOS from perivascular resident macrophages was found to be important for BMDC infiltration, since mice deficient in iNOS (Inos(-/-)) and mice with iNOS that had been inhibited by 1400W displayed reduced BMDC infiltration.	bmdc	80-84	nitric oxide synthase 2, inducible	Mus musculus	6-10
21057001-7	2010	Local iNOS from perivascular resident macrophages was found to be important for BMDC infiltration, since mice deficient in iNOS (Inos(-/-)) and mice with iNOS that had been inhibited by 1400W displayed reduced BMDC infiltration.	bmdc	210-214	nitric oxide synthase 2, inducible	Mus musculus	6-10
21108471-5	2010	Mechanistic studies highlighted that SIRP-alpha ligation by CD47-Fc on BMDC did not impair Ag uptake, Ag presentation and Ag-specific DO11.10 Tg Th2 priming and effector function in vitro, whereas in vivo administration of CD47-Fc or CD47-Fc-pretreated BMDC inhibited Tg T-cell proliferation, pinpointing that altered DC trafficking accounts for defective Th priming.	bmdc	71-75	signal-regulatory protein alpha	Mus musculus	37-47
21041655-4	2010	In the presence of LPS or CpG, Ahr-deficient (Ahr(-/-)) mature BMDC induced immune responses characterized by reduced Kyn and IL-10 production compared with results observed with tolerogenic mature WT BMDC.	bmdc	63-67	aryl hydrocarbon receptor	Homo sapiens	31-34
21041655-4	2010	In the presence of LPS or CpG, Ahr-deficient (Ahr(-/-)) mature BMDC induced immune responses characterized by reduced Kyn and IL-10 production compared with results observed with tolerogenic mature WT BMDC.	bmdc	63-67	interleukin 10	Homo sapiens	126-131
20534768-6	2010	In the metaanalysis, we found the OPG SNP (rs4355801) and the RANK SNP (rs3018362) to be significantly associated with BMDC.	bmdc	119-123	basic transcription factor 3 pseudogene 11	Homo sapiens	34-37
20813969-5	2010	By comparing both in vitro secretion and in vivo local induction of acute phase inflammatory cytokines by these cells, we identified monocyte chemoattractant factor 1 and tumor necrosis factor alpha as potential mediators of BMDC-induced tissue repair.	bmdc	225-229	tumor necrosis factor	Mus musculus	133-198
20813969-6	2010	In vivo analysis of BMDC-treated ischemic limbs and cutaneous wounds revealed that the production of monocyte chemoattractant factor 1 by exogenous and endogenous BMDCs is essential for BMDC-mediated vascular growth and tissue healing, while the inability of BMDCs to produce tumor necrosis factor alpha appears to play a lesser but still meaningful role.	bmdc	20-24	tumor necrosis factor	Mus musculus	276-303
20231889-4	2010	Loss of Jak2 significantly impaired DC development as manifested by reduced BMDC yield, smaller spleen size and reduced percentage of DCs in total splenocytes.	bmdc	76-80	Janus kinase 2	Mus musculus	8-12
20661430-8	2010	Interestingly, we see that the BMDC activation is primarily due to signaling through the IFNAR and only marginally induced by the initial infection.	bmdc	31-35	interferon alpha and beta receptor subunit 1	Homo sapiens	89-94
20525882-5	2010	In contrast, transfer of these same OVA/alphaGalCer BMDCs into IFN-gamma-deficient (IFN-gamma(-/-)) mice enhanced the development of these lung allergic responses, which was reversed by exogenous IFN-gamma treatment following OVA-BMDC transfer.	bmdc	52-56	interferon gamma	Mus musculus	63-72
20525882-5	2010	In contrast, transfer of these same OVA/alphaGalCer BMDCs into IFN-gamma-deficient (IFN-gamma(-/-)) mice enhanced the development of these lung allergic responses, which was reversed by exogenous IFN-gamma treatment following OVA-BMDC transfer.	bmdc	52-56	interferon gamma	Mus musculus	84-93
20525882-5	2010	In contrast, transfer of these same OVA/alphaGalCer BMDCs into IFN-gamma-deficient (IFN-gamma(-/-)) mice enhanced the development of these lung allergic responses, which was reversed by exogenous IFN-gamma treatment following OVA-BMDC transfer.	bmdc	52-56	interferon gamma	Mus musculus	84-93
20350561-12	2010	AhR activation by TCDD modulated BMDC uptake of both soluble and particulate antigens.	bmdc	33-37	aryl-hydrocarbon receptor	Mus musculus	0-3
20373289-3	2010	Immature, IL-10, TGF-beta and 1alpha,25-dihydroxyvitamin D(3)-modulated BMDC all induced tolerance to male skin in female TCR transgenic A1.RAG mice, and the modulated DC also tolerized after exposure to the TLR4-ligand LPS.	bmdc	72-76	interleukin 10	Mus musculus	10-15
20373289-3	2010	Immature, IL-10, TGF-beta and 1alpha,25-dihydroxyvitamin D(3)-modulated BMDC all induced tolerance to male skin in female TCR transgenic A1.RAG mice, and the modulated DC also tolerized after exposure to the TLR4-ligand LPS.	bmdc	72-76	toll-like receptor 4	Mus musculus	208-212
20145551-5	2010	We observed that BMDC, matured with a cytokine cocktail (tumor necrosis factor-alpha, interleukin-beta, interleukin-6, prostaglandin E2), strongly expressed CCR7.	bmdc	17-21	C-C motif chemokine receptor 7	Homo sapiens	157-161
19761873-7	2009	Conversely, BMDC avoided the expression of IL-1beta at days 30 and 60 and TGF-beta only at day 30.	bmdc	12-16	interleukin 1 beta	Mus musculus	43-51
20145551-5	2010	We observed that BMDC, matured with a cytokine cocktail (tumor necrosis factor-alpha, interleukin-beta, interleukin-6, prostaglandin E2), strongly expressed CCR7.	bmdc	17-21	tumor necrosis factor	Homo sapiens	38-84
20145551-5	2010	We observed that BMDC, matured with a cytokine cocktail (tumor necrosis factor-alpha, interleukin-beta, interleukin-6, prostaglandin E2), strongly expressed CCR7.	bmdc	17-21	interleukin 6	Homo sapiens	104-117
20130363-0	2010	[Effect of RelB-silenced BMDC pulsed with Talpha146~162 on immunoreaction of T cells primed with TAChR].	bmdc	25-29	avian reticuloendotheliosis viral (v-rel) oncogene related B	Mus musculus	11-15
20193348-13	2009	CONCLUSION: Mobilization of BMDC by G-CSF showed a protective effect on lung injury induced by bleomycin in mice, but did not have significant influence on survival time.	bmdc	28-32	colony stimulating factor 3 (granulocyte)	Mus musculus	36-41
19968878-7	2009	When iGb3 was incubated with BMDC and tested with DN32D3 cells, IL-2 was equally produced indicating iNKT cell activation.	bmdc	29-33	alpha 1,3-galactosyltransferase 2 (isoglobotriaosylceramide synthase)	Mus musculus	5-9
19968878-7	2009	When iGb3 was incubated with BMDC and tested with DN32D3 cells, IL-2 was equally produced indicating iNKT cell activation.	bmdc	29-33	interleukin 2	Mus musculus	64-68
19759906-4	2009	Here, we demonstrate by bone marrow transplantation/reconstitution and genetic lineage-tracing experiments that BMDC integrate into tumor-associated lymphatic vessels in the Rip1Tag2 mouse model of insulinoma and in the TRAMP-C1 prostate cancer transplantation model, and that the integrated BMDC originate from the myelomonocytic lineage.	bmdc	112-116	tumor necrosis factor receptor superfamily, member 25	Mus musculus	220-225
19342636-5	2009	NECA-treated BMDC also expressed reduced levels of MHC class II and CD86 and were less effective at stimulating CD4(+) T cell proliferation and IL-2 production compared with BMDC exposed to vehicle control.	bmdc	13-17	CD86 antigen	Mus musculus	68-72
19477431-3	2009	Here, we demonstrate that both IL-8 and angiogenin contribute to the complementary pathways of angiogenesis and BMDC mobilization to increase tumor growth.	bmdc	112-116	C-X-C motif chemokine ligand 8	Homo sapiens	31-35
19342636-5	2009	NECA-treated BMDC also expressed reduced levels of MHC class II and CD86 and were less effective at stimulating CD4(+) T cell proliferation and IL-2 production compared with BMDC exposed to vehicle control.	bmdc	13-17	interleukin 2	Mus musculus	144-148
18775800-9	2008	BMDC-stimulated IFN-gamma production from T-cells was significantly lower in NC/Nga or BALB/c mice than in C57BL/6J mice, whereas IL-4 production was significantly greater in NC/Nga and C57BL/6J mice than in BALB/c mice.	bmdc	0-4	interferon gamma	Mus musculus	16-25
18775800-10	2008	Taken together, GM-CSF-stimulated differentiation of BMDC was more accelerated in atopic prone NC/Nga mice than in the other strains of mice.	bmdc	53-57	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	16-22
18515407-6	2008	Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung.	bmdc	17-21	dipeptidylpeptidase 4	Mus musculus	65-69
18991288-7	2008	FGL2 inhibited the maturation of BMDC from FcgammaRIIB+/+ mice but not from FcgammaRIIB(-/-) mice and induced apoptosis in the FcgammaRIIB+ mouse B-cell line (A20) but not the A20IIA1.6 cell line that does not express FcgammaRIIB.	bmdc	33-37	fibrinogen-like protein 2	Mus musculus	0-4
18991288-7	2008	FGL2 inhibited the maturation of BMDC from FcgammaRIIB+/+ mice but not from FcgammaRIIB(-/-) mice and induced apoptosis in the FcgammaRIIB+ mouse B-cell line (A20) but not the A20IIA1.6 cell line that does not express FcgammaRIIB.	bmdc	33-37	Fc receptor, IgG, low affinity IIb	Mus musculus	43-54
18515407-6	2008	Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung.	bmdc	17-21	chemokine (C-X-C motif) ligand 12	Mus musculus	133-138
18515407-6	2008	Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung.	bmdc	17-21	chemokine (C-X-C motif) ligand 12	Mus musculus	139-145
18515407-6	2008	Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung.	bmdc	17-21	chemokine (C-X-C motif) receptor 4	Mus musculus	147-152
18250429-5	2008	When infected with Chlamydia, BMDC secrete increased TNF-alpha, IL-6, IL-10, IL-12, and IL-13.	bmdc	30-34	interleukin 10	Mus musculus	70-75
18375954-4	2008	We report higher IL-23p19 mRNA accumulation and protein secretion in LPS-stimulated BMDC isolated from IL-10(-/-) compared with WT mice.	bmdc	84-88	interleukin 23, alpha subunit p19	Mus musculus	17-25
18375954-4	2008	We report higher IL-23p19 mRNA accumulation and protein secretion in LPS-stimulated BMDC isolated from IL-10(-/-) compared with WT mice.	bmdc	84-88	interleukin 10	Mus musculus	103-108
18250429-5	2008	When infected with Chlamydia, BMDC secrete increased TNF-alpha, IL-6, IL-10, IL-12, and IL-13.	bmdc	30-34	interleukin 13	Mus musculus	88-93
18250429-6	2008	OVA peptide-pulsed infected BMDC induced significant proliferation of transgenic CD4(+) DO11.10 (D10) T cells, strongly inhibited IFN-gamma secretion by D10 cells, and promoted a Th2 phenotype.	bmdc	28-32	interferon gamma	Mus musculus	130-139
17467810-7	2007	In addition, pre-exposure of BMDC to Tk produced increased levels of IL-10, but decreased levels of IL-12, following subsequent lipopolysaccharide (LPS) stimulation.	bmdc	29-33	interleukin 10	Mus musculus	69-74
18179826-5	2008	In the enzyme assay using cellular extracts of BMDC, the IDO activity of BMDC stimulated with CpG was enhanced by the addition of a NO synthase (NOS) inhibitor, suggesting that IDO activity was suppressed by NO production.	bmdc	47-51	indoleamine 2,3-dioxygenase 1	Mus musculus	57-60
18179826-5	2008	In the enzyme assay using cellular extracts of BMDC, the IDO activity of BMDC stimulated with CpG was enhanced by the addition of a NO synthase (NOS) inhibitor, suggesting that IDO activity was suppressed by NO production.	bmdc	47-51	nitric oxide synthase 1, neuronal	Mus musculus	132-143
18179826-5	2008	In the enzyme assay using cellular extracts of BMDC, the IDO activity of BMDC stimulated with CpG was enhanced by the addition of a NO synthase (NOS) inhibitor, suggesting that IDO activity was suppressed by NO production.	bmdc	47-51	indoleamine 2,3-dioxygenase 1	Mus musculus	177-180
18179826-5	2008	In the enzyme assay using cellular extracts of BMDC, the IDO activity of BMDC stimulated with CpG was enhanced by the addition of a NO synthase (NOS) inhibitor, suggesting that IDO activity was suppressed by NO production.	bmdc	73-77	indoleamine 2,3-dioxygenase 1	Mus musculus	57-60
18179826-5	2008	In the enzyme assay using cellular extracts of BMDC, the IDO activity of BMDC stimulated with CpG was enhanced by the addition of a NO synthase (NOS) inhibitor, suggesting that IDO activity was suppressed by NO production.	bmdc	73-77	nitric oxide synthase 1, neuronal	Mus musculus	132-143
18179826-5	2008	In the enzyme assay using cellular extracts of BMDC, the IDO activity of BMDC stimulated with CpG was enhanced by the addition of a NO synthase (NOS) inhibitor, suggesting that IDO activity was suppressed by NO production.	bmdc	73-77	indoleamine 2,3-dioxygenase 1	Mus musculus	177-180
18075238-4	2007	This study examined whether G-CSF and/or resveratrol affect the recruitment of BMDC into vascular endothelial cells and renal tubular cells and the kidney function after I/R injury.	bmdc	79-83	colony stimulating factor 3 (granulocyte)	Mus musculus	28-33
17615582-8	2007	When an hsp110-rat neu (intracellular domain) heat shock complex vaccine is used to pulse mouse bmDC in vitro, an induction of IFN-gamma secretion is observed by CD8+ T lymphocytes isolated from vaccine-immunized mice.	bmdc	96-100	heat shock protein family A (Hsp70) member 4	Rattus norvegicus	8-14
17615582-8	2007	When an hsp110-rat neu (intracellular domain) heat shock complex vaccine is used to pulse mouse bmDC in vitro, an induction of IFN-gamma secretion is observed by CD8+ T lymphocytes isolated from vaccine-immunized mice.	bmdc	96-100	interferon gamma	Mus musculus	127-136
17521735-3	2007	In this study, we modified a BMDC vaccine by incorporating the SLC mature peptide gene.	bmdc	29-33	chemokine (C-C motif) ligand 21A (serine)	Mus musculus	63-66
18032545-6	2008	When anti-HGF IgG was injected in the earlier stage, tubular cell proliferation was inhibited, leading to an increase in BMDC in renal tubules.	bmdc	121-125	hepatocyte growth factor	Mus musculus	10-13
18032545-9	2008	Thus possible cascades include 1) inhibition of tubular cell proliferation by neutralizing HGF leads to renal hypoxia and SDF1 upregulation; and 2) BMDC are eventually engrafted in tubules through SDF1-mediated chemotaxis.	bmdc	148-152	hepatocyte growth factor	Mus musculus	91-94
18032545-9	2008	Thus possible cascades include 1) inhibition of tubular cell proliferation by neutralizing HGF leads to renal hypoxia and SDF1 upregulation; and 2) BMDC are eventually engrafted in tubules through SDF1-mediated chemotaxis.	bmdc	148-152	chemokine (C-X-C motif) ligand 12	Mus musculus	197-201
18032545-10	2008	Inversely, administration of recombinant HGF suppressed the renal hypoxia, SDF1 upregulation, and BMDC engraftment in ARF mice by enhancing resident tubular cell proliferation.	bmdc	98-102	hepatocyte growth factor	Mus musculus	41-44
16339999-6	2006	Co-culture of BMDC with immune complexes of OVA and IgG anti-OVA together with OVA-sensitized spleen mononuclear cells resulted in increases in IL-13 production.	bmdc	14-18	interleukin 13	Mus musculus	144-149
17378899-8	2007	Monoclonal antibodies that block IL-23 showed further that BMDC-derived IL-23 was required for production of IL-17 in this experimental model.	bmdc	59-63	interleukin 23, alpha subunit p19	Mus musculus	33-38
17378899-8	2007	Monoclonal antibodies that block IL-23 showed further that BMDC-derived IL-23 was required for production of IL-17 in this experimental model.	bmdc	59-63	interleukin 23, alpha subunit p19	Mus musculus	72-77
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	bmdc	29-33	tumor necrosis factor	Mus musculus	82-91
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	bmdc	29-33	interleukin 1 alpha	Mus musculus	93-102
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	bmdc	29-33	interleukin 6	Mus musculus	104-108
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	bmdc	29-33	mast cell protease 1	Mus musculus	138-143
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	bmdc	29-33	interleukin 10	Mus musculus	208-213
15650175-10	2005	Candidate effectors of alternative antiviral pathways were those genes induced by virus infection or IFN-alpha/beta treatment in 129 Sv/Ev and TD-derived BMDC but not in virus-infected or IFN-alpha/beta-treated IFNAR1-/- cells.	bmdc	154-158	interferon alpha	Mus musculus	101-110
16508978-5	2006	BMDC activation was determined by flow cytometry (CD40, CD86).	bmdc	0-4	CD40 molecule	Homo sapiens	50-54
16508978-5	2006	BMDC activation was determined by flow cytometry (CD40, CD86).	bmdc	0-4	CD86 molecule	Homo sapiens	56-60
15546160-3	2005	This study establishes that bone marrow-derived epidermal cells are proliferative and, moreover, demonstrates for the first time that BMDC can localize to a known stem cell niche: the CD34-positive bulge region of mouse hair follicles.	bmdc	134-138	CD34 antigen	Mus musculus	184-188
15187118-7	2004	Although WT bone marrow cultures died within 4 wk, IL-6(-/-) cultures continued to generate BMDC for >120 days, although the BMDC became immature and less functional.	bmdc	92-96	interleukin 6	Mus musculus	51-55
15533866-6	2004	Administration of AMD3100, which specifically blocks binding of SDF-1 to its endogenous receptor CXCR4, diminished BMDC recruitment after MI by 64.2+/-5.5% (P<0.05), strongly suggesting a requirement for SDF-1 in BMDC recruitment to the infarcted heart.	bmdc	115-119	C-X-C motif chemokine ligand 12	Homo sapiens	64-69
15919369-8	2004	We found that the BMDC from DBA/2 mice showed significant upregulation of Toll-like receptor-2 and 4 genes expression, secretion of IL-12 (p<0.05) and modest increase in T cell co-stimulatory molecules as compared to BMDC from BALB/c mice.	bmdc	18-22	toll-like receptor 2	Mus musculus	74-100
15128817-3	2004	In contrast, all mice vaccinated with a single dose of Leishmania major Ag-pulsed BMDC stimulated by prior in vitro exposure to CpG-containing oligodeoxynucleotides (ODN) were completely protected, had a dramatic reduction in parasite burden, and developed an Ag-specific Th1 response.	bmdc	82-86	negative elongation factor complex member C/D, Th1l	Mus musculus	272-275
11369698-8	2001	Antigen uptake and processing of HA-IL-2 by BMDC was required since fixing BMDC, prior to antigen exposure, greatly reduced their ability to activate A5 cells.	bmdc	44-48	interleukin 2	Mus musculus	36-40
12429720-6	2002	The presence of IL-4 enhanced the yield and maturation of BMDC but inhibited LPS-induced IL-10 production by eDC.	bmdc	58-62	interleukin 4	Homo sapiens	16-20
14597102-7	2003	Finally, preincubation of BMDC with LPS in presence of the specific beta2-AR agonist salbutamol impaired their chemotactic response to CCL19 and CCL21 and this effect was neutralized by anti-IL-10 mAb.	bmdc	26-30	adrenergic receptor, beta 2	Mus musculus	68-76
14597102-7	2003	Finally, preincubation of BMDC with LPS in presence of the specific beta2-AR agonist salbutamol impaired their chemotactic response to CCL19 and CCL21 and this effect was neutralized by anti-IL-10 mAb.	bmdc	26-30	chemokine (C-C motif) ligand 19	Mus musculus	135-140
14597102-7	2003	Finally, preincubation of BMDC with LPS in presence of the specific beta2-AR agonist salbutamol impaired their chemotactic response to CCL19 and CCL21 and this effect was neutralized by anti-IL-10 mAb.	bmdc	26-30	interleukin 10	Mus musculus	191-196
12460194-5	2002	We demonstrate that IL-10 can prevent BMDC maturation, as measured by both cytokine production and T-cell priming capacity in vitro.	bmdc	38-42	interleukin 10	Mus musculus	20-25
12356687-5	2002	In response to lipopolysaccharide (LPS), IFN-beta gene expression was augmented in both wild-type and MyD88-deficient BMDC.	bmdc	118-122	interferon beta 1	Homo sapiens	41-49
12356687-5	2002	In response to lipopolysaccharide (LPS), IFN-beta gene expression was augmented in both wild-type and MyD88-deficient BMDC.	bmdc	118-122	MYD88 innate immune signal transduction adaptor	Homo sapiens	102-107
11792384-5	2002	Furthermore, F-18-labeled BMDC stimulated allogeneic T cells in a mixed leukocyte reaction as potently as did sham-treated BMDC and migrated towards secondary lymphoid tissue chemokine (SLC) in a chemotaxis assay in vitro with the same efficiency as sham-treated BMDC.	bmdc	26-30	chemokine (C-C motif) ligand 21A (serine)	Mus musculus	149-184
11792384-5	2002	Furthermore, F-18-labeled BMDC stimulated allogeneic T cells in a mixed leukocyte reaction as potently as did sham-treated BMDC and migrated towards secondary lymphoid tissue chemokine (SLC) in a chemotaxis assay in vitro with the same efficiency as sham-treated BMDC.	bmdc	26-30	chemokine (C-C motif) ligand 21A (serine)	Mus musculus	186-189
11369698-8	2001	Antigen uptake and processing of HA-IL-2 by BMDC was required since fixing BMDC, prior to antigen exposure, greatly reduced their ability to activate A5 cells.	bmdc	75-79	interleukin 2	Mus musculus	36-40
9886383-8	1999	In correspondence to their maturation stage, BmDC cultured in the presence of CD40L exhibited the most potent immunostimulatory effects.	bmdc	45-49	CD40 ligand	Mus musculus	78-83
10918477-6	2000	Consistent with DC activation, FACs analysis showed BMDC infected with Ad vectors up-regulated the surface expression of B7-2, ICAM-1 and MHC II.	bmdc	52-56	CD86 antigen	Mus musculus	121-125
10918477-6	2000	Consistent with DC activation, FACs analysis showed BMDC infected with Ad vectors up-regulated the surface expression of B7-2, ICAM-1 and MHC II.	bmdc	52-56	intercellular adhesion molecule 1	Mus musculus	127-133
10918477-6	2000	Consistent with DC activation, FACs analysis showed BMDC infected with Ad vectors up-regulated the surface expression of B7-2, ICAM-1 and MHC II.	bmdc	52-56	histocompatibility-2, MHC	Mus musculus	138-144
10925779-8	2000	It has been found that local pretreatment with BMDC inhibits growth of a subsequent challenge inoculum of the MK16 cells.	bmdc	47-51	potassium voltage-gated channel, shaker-related, subfamily, member 6	Mus musculus	110-114
9286353-7	1997	Incubation of bone marrow-derived DC with IL-4 (100 U/ml) resulted in downregulation of CD14 surface expression, whereas exposure of BmDC to LPS (1 microgram/ml) led to upregulation of CD14.	bmdc	133-137	CD14 antigen	Mus musculus	185-189
9022030-6	1997	We show that BMDC presented exogenous ovalbumin to a T cell hybridoma more effectively, more rapidly, and at lower exogenous antigen concentrations than BM macrophages on a cell-for-cell basis.	bmdc	13-17	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	38-47
9022030-9	1997	Finally, PMA-stimulated BMDC exposed to exogenous ovalbumin in vitro were able to prime an antigen-specific cytotoxic T lymphocyte response following adoptive transfer in vivo.	bmdc	24-28	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	50-59
32807859-5	2020	SOCS3-/- DCs slightly attenuated BMDC-induced immunogenic tolerance.	bmdc	33-37	suppressor of cytokine signaling 3	Mus musculus	0-5